O'Brien Patrick's Form 4 filing
Arrowhead Pharmaceuticals, Inc. (ARWR) · filed Jan 5, 2026
- Accession no.
- 0001627183-26-000001
- Filed
- Jan 5, 2026
- Trade date
- Dec 31, 2025-Jan 5, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 17 non-derivative transactions. Open-market sales total $3.12M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| O'Brien PatrickCIK 0001627183 | Officer (COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | Common Stock | GGiftDisposed | −560 | $0.00 | $0 | 526,641 | Direct | |
| Dec 31, 2025 | Common Stock | GGiftDisposed | −560 | $0.00 | $0 | 526,081 | Direct | |
| Dec 31, 2025 | Common Stock | GGiftDisposed | −560 | $0.00 | $0 | 525,521 | Direct | |
| Dec 31, 2025 | Common Stock | GGiftDisposed | −560 | $0.00 | $0 | 524,961 | Direct | |
| Dec 31, 2025 | Common Stock | GGiftDisposed | −560 | $0.00 | $0 | 524,401 | Direct | |
| Jan 5, 2026 | Common Stock | SSaleDisposed | −4,368 | $61.20F5 | −$267,321.6 | 520,033 | Direct | |
| Jan 5, 2026 | Common Stock | SSaleDisposed | −6,164 | $62.23F6 | −$383,585.72 | 513,869 | Direct | |
| Jan 5, 2026 | Common Stock | SSaleDisposed | −13,451 | $62.96F7 | −$846,874.96 | 500,418 | Direct | |
| Jan 5, 2026 | Common Stock | SSaleDisposed | −11,842 | $63.84F8 | −$755,993.28 | 488,576 | Direct | |
| Jan 5, 2026 | Common Stock | SSaleDisposed | −2,700 | $64.44F9 | −$173,988 | 485,876 | Direct | |
| Jan 5, 2026 | Common Stock | SSaleDisposed | −900 | $66.01F10 | −$59,409 | 484,976 | Direct | |
| Jan 5, 2026 | Common Stock | SSaleDisposed | −313 | $68.00 | −$21,284 | 484,663 | Direct | |
| Jan 5, 2026 | Common Stock | SSaleDisposed | −600 | $61.12F11 | −$36,672 | 484,063 | Direct | |
| Jan 5, 2026 | Common Stock | SSaleDisposed | −900 | $62.25F12 | −$56,025 | 483,163 | Direct | |
| Jan 5, 2026 | Common Stock | SSaleDisposed | −5,873 | $62.91F13 | −$369,470.43 | 477,290 | Direct | |
| Jan 5, 2026 | Common Stock | SSaleDisposed | −2,336 | $64.04F14 | −$149,597.44 | 474,954 | Direct | |
| Jan 5, 2026 | Common Stock | SSaleDisposed | −46 | $68.00 | −$3,128 | 474,908 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F5
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.85 to $61.64, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $62.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.55 to $63.38, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F8
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.41 to $64.35, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F9
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.36 to $64.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F10
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.85 to $66.12, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F11
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.75 to $61.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F12
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.84 to $62.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F13
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.54 to $63.39, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F14
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.58 to $64.46, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.